Toll-like receptor genetic variants and colorectal cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

1. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility.BioMed research international · 2021
   Review
2. Epistatic effect of TLR3 and cGAS-STING-IKKε-TBK1-IFN signaling variants on colorectal cancer risk.Cancer medicine · 2020
   Observational
3. Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.PloS one · 2018
   Article
4. Coding variants in NOD-like receptors: An association study on risk and survival of colorectal cancer.PloS one · 2018
   Article
5. Microbiota, Inflammation and Colorectal Cancer.International journal of molecular sciences · 2017
   Review
6. Pattern Recognition Receptors in Cancer Progression and Metastasis.Cancer growth and metastasis · 2015
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 4 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as